

ORIGINAL ARTICLE

Searching for biomarkers of CDKL5 disorder: early-onset visual impairment in CDKL5 mutant mice

Raffaele Mazziotti^{1,†}, Leonardo Lupori^{2,†}, Giulia Sagona¹,
Mariangela Gennaro^{1,3}, Grazia Della Sala^{1,3}, Elena Putignano³ and
Tommaso Pizzorusso^{1,2,3,*}

¹Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Area San Salvi – Pad. 26, 50135 Florence, Italy, ²BIO@SNS Lab, Scuola Normale Superiore via Moruzzi, 1 56124 Pisa, Italy and ³Institute of Neuroscience, National Research Council, via Moruzzi, 1 56124 Pisa, Italy

*To whom correspondence should be addressed. Tel: +39 0503153167; Fax: +39 0503153220; Email: tommaso.pizzorusso@in.cnr.it

Abstract

CDKL5 disorder is a neurodevelopmental disorder still without a cure. Murine models of CDKL5 disorder have been recently generated raising the possibility of preclinical testing of treatments. However, unbiased, quantitative biomarkers of high translational value to monitor brain function are still missing. Moreover, the analysis of treatment is hindered by the challenge of repeatedly and non-invasively testing neuronal function. We analyzed the development of visual responses in a mouse model of CDKL5 disorder to introduce visually evoked responses as a quantitative method to assess cortical circuit function. Cortical visual responses were assessed in CDKL5 null male mice, heterozygous females, and their respective control wild-type littermates by repeated transcranial optical imaging from P27 until P32. No difference between wild-type and mutant mice was present at P25–P26 whereas defective responses appeared from P27–P28 both in heterozygous and homozygous CDKL5 mutant mice. These results were confirmed by visually evoked potentials (VEPs) recorded from the visual cortex of a different cohort. The previously imaged mice were also analyzed at P60–80 using VEPs, revealing a persistent reduction of response amplitude, reduced visual acuity and defective contrast function. The level of adult impairment was significantly correlated with the reduction in visual responses observed during development. Support vector machine showed that multi-dimensional visual assessment can be used to automatically classify mutant and wt mice with high reliability. Thus, monitoring visual responses represents a promising biomarker for preclinical and clinical studies on CDKL5 disorder.

Introduction

Cyclin-dependent kinase-like 5 (CDKL5) disorder, also known as early infantile epileptic encephalopathy type 2 (EIEE2, OMIM number: #300672) is a severe neurological condition characterized by early-onset seizures in the first month of life, intellectual disability, motor and social impairment. This disease has

recently been considered as an autonomous etiopathological entity (1), with a clearly distinct genetic and clinical phenotype respect to other similar infantile encephalopathies such as Rett syndrome (RTT) and X-linked infantile spasm syndrome 1 (ISSX1). No effective treatment is currently available for this disease. At a molecular level, CDKL5 is a serine/threonine kinase

[†]The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.

Received: January 22, 2017. Revised: March 23, 2017. Accepted: March 25, 2017

© The Author 2017. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

that is highly expressed in the central nervous system. Intracellular localization of CDKL5 appears to vary in different brain areas and during development with expression present both in the cytosolic and nuclear fractions (2). CDKL5 was also found to be localized in postsynaptic structures, where it can regulate dendritic spine maturation and density, and modulate excitatory synaptic function (3,4). The synaptic localization of CDKL5 seems to be mediated by its interaction with the palmitoylated form of postsynaptic density protein 95 (PSD-95) (5,6) or by the formation of a complex involving PSD-95 and NGL-1 (3). In mice, CDKL5 is strongly upregulated postnatally with high levels of expression in the forebrain (2,7,8).

Recently, CDKL5 loss-of-function murine models that recapitulate some aspects of the human disease have become available (9,10), raising the possibility of preclinical testing of treatments. However, unbiased, quantitative biomarkers of high translational value to monitor brain function are still missing. Moreover, the analysis of treatment and washout effects are hindered by the challenge of repeatedly and non-invasively testing neuronal function over the course of the disorder. Recent work introduced the use of visually evoked responses as a quantitative method to assess cortical circuit function in RTT patients carrying MeCP2 mutations (11). The results obtained in humans revealed a good correlation with the results in the mouse model (11,12) suggesting that the analysis of visual phenotype could also be extended to other diseases, including the CDKL5 disorder, in which abnormal function of cortical circuits can be hypothesized and animal models are available. Indeed, clinical studies indicated that several CDKL5 patients show visual impairments (13–16) and abnormal electroencephalographic (17) waveforms deriving from impaired activity of the cerebral cortex, in keeping with findings of morphofunctional alterations in sensory cortical circuits of *cdkl5* mutant mice (4,9,10). Thus, we investigated the developmental trajectory of cortical visual responses in male mice totally missing CDKL5, and in heterozygous *cdkl5* females, better recapitulating the mosaic distribution of mutant cells present in the majority of CDKL5 patients. Two independent techniques were used: longitudinal transcranial intrinsic optical signal (IOS) imaging and intracortical VEP recordings. The data showed the presence of an impairment of visual response both in male and in female mutants, first detectable at P27. This early alteration of visual responses was correlated with impairments of different parameters of cortical visual function in adulthood, and can be exploited as a classifying biomarker providing rational targets for treatment assessment.

Results

Longitudinal IOS imaging reveals decreased amplitude of cortical visual responses in developing *cdkl5* mutants

To determine the impact of *cdkl5* mutation on visual cortical development we examined cortical responses to visual stimulation using intact skull repeated IOS imaging in juvenile animals, and tracking response maturation in binocular visual cortex during visual development (P25–32) (18). We examined IOS responses in the same subjects, both male *cdkl5* null and female heterozygous mice compared with their age and sex matched wt littermates, at three different developmental stages (Fig. 1A). Figure 2A and E shows typical examples of responses from the different experimental groups consisting in a decrease in reflectance (dark area) induced by visual stimulation in the visual

cortex. Data quantitation showed that at the first age tested (P25–26), the amplitude of the responses to contralateral eye stimulation was comparable between *cdkl5* null and control mice, however, at later ages (P27–28 and P31–32) *cdkl5* null mice showed a significantly reduced response with respect to wt (Fig. 2B, wt $N=9$, *cdkl5* null $N=7$; two-way ANOVA genotype $P=0.035$, *post hoc* Holm–Sidak wt versus mutants P25–26 $P=0.91$, P27–28 $P=0.0016$, P31–32 $P=0.0047$). The responses to the ipsilateral eye showed a similar pattern: no difference between genotypes at P25–26 and significantly reduced amplitude in *cdkl5* null mice at P27–28 and at P31–32 (Fig. 2C, wt $N=9$, *cdkl5* null $N=7$; two-way ANOVA genotype $P=0.0017$, *post hoc* Holm–Sidak wt versus mutants P25–26 $P=0.5$, P27–28 $P=0.024$, P31–32 $P=0.0028$). Interestingly, female heterozygous *cdkl5* mice also showed a similar developmental impairment of contralateral evoked responses, but preserved ipsilateral response amplitude (Fig. 2F and G, wt $N=11$, *cdkl5* het $N=7$; Contralateral responses: two-way ANOVA time \times genotype $P=0.017$, *post hoc* Holm–Sidak wt versus mutants P25–26 $P=0.53$, P27–28 $P=0.046$, P31–32 $P=0.049$; Ipsilateral responses: two-way ANOVA time \times genotype $P=0.17$, genotype $P=0.87$). This differential effect on ipsilateral and contralateral responses resulted in an abnormal ocular dominance index (ODI) biased toward ipsilateral eye in heterozygous mutants with respect to wt (Fig. 2H, wt $N=11$, *cdkl5* het $N=7$; *t*-test $P=0.003$). No change in ODI was present in null mice with respect to controls (Fig. 2D, wt $N=9$, *cdkl5* null $N=7$; *t*-test $P=0.87$). Thus, defective development of visual responses is present after P27 both in null and heterozygous *cdkl5* mutant mice.

Impaired VEP responses in juvenile and adult *cdkl5* mutants

To assess cortical visual responses in *cdkl5* mutants using a different technique, we recorded intracortical VEP responses to pattern reversal by means of a multielectrode inserted into the binocular visual cortex of p27–32 mice, a time point representing the onset of the visual response deficit previously observed by IOS imaging in heterozygous and null mice. VEP results reproduced IOS data showing a reduced VEP amplitude in male *cdkl5* null mice for both contralateral and ipsilateral stimulation (Supplementary Material, Fig. S1, wt $N=5$, *cdkl5* null $N=4$; two-way ANOVA genotype $P<0.001$, *post hoc* Holm–Sidak wt versus mutants Ipsilateral eye $P=0.04$, Contralateral eye $P<0.001$), and reduced VEP amplitude for contralateral eye stimulation in heterozygous *cdkl5* mice (Supplementary Material, Fig. S1, wt $N=4$, *cdkl5* het $N=5$; two way ANOVA interaction eye \times genotype $P=0.014$, *post hoc* Holm–Sidak wt versus mutants Ipsilateral eye $P=0.13$, Contralateral eye $P<0.001$).

To investigate whether the developmental visual impairment persists into adulthood we recorded VEPs in P60–P80 mice. To establish whether the defect observed in juvenile mice was correlated with adult visual cortical responses, we analyzed the same mice that were studied during development by means of IOS imaging, a non-terminal procedure that allows recovery of the animal at the end of the procedure. We found that VEP amplitude was reduced in adult *cdkl5* null mice for both contralateral and ipsilateral eye stimulation (Fig. 3A, wt $N=6$, *cdkl5* null $N=6$; two way ANOVA genotype $P<0.0001$, *post hoc* Holm–Sidak wt versus mutants Ipsilateral eye $P=0.028$, Contralateral eye $P=0.0001$). Similarly, contralateral, but not ipsilateral, eye responses were significantly reduced in heterozygous *cdkl5* females (Fig. 3C, wt $N=8$, *cdkl5* het $N=8$; two way ANOVA




Figure 1. (A) Sketch of the experimental protocol. (B) Picture of the 3D printed imaging chamber. (C) Example of $\Delta R/R$ visual responses. Shaded area represents duration of the visual stimulation. Horizontal scale bar=1s, vertical scale bar ($\Delta R/R$)= 2×10^{-4} . (D) Flow chart of image processing for automated binocular visual cortex ROI generation. Frame size: 2×2 mm.

eye \times genotype $P = 0.029$, post hoc Holm–Sidak wt versus mutants Ipsilateral eye $P = 0.31$, Contralateral eye $P = 0.0004$) resulting in an abnormal ODI in *cdkl5* heterozygous mice (Fig. 3D, wt $N = 8$, *cdkl5* het $N = 8$; t-test $P = 0.03$), but not in *cdkl5* null males (Fig. 3B, wt $N = 6$, *cdkl5* null $N = 6$; t-test $P = 0.22$). No difference was observed between VEP waveforms in any of the genotypes (Supplementary Material, Fig. S2). These data, obtained in adult mice, overlap with the results found during early development using IOS imaging.

VEPs are usually employed to assess visual parameters such as contrast sensitivity and spatial visual acuity that well correlate with vision assessed behaviorally in both mice and humans (11,19–22). To investigate whether contrast responses are affected by *cdkl5* mutation, we recorded VEPs in response to gratings of different contrast in *cdkl5* null and heterozygous animals (Fig. 4A and B). Contrast response curves were fitted with a Naka–Rushton function (23,24) to derive two parameters: C_{50} representing the contrast eliciting the half-maximal response, and N representing the slope of the curve. We found that *cdkl5* mutants reached half maximum responses at much higher contrast values than wt mice (Fig. 4C and D; wt $N = 5$, *cdkl5* null $N = 6$; t-test $P = 0.035$; wt $N = 7$, *cdkl5* het $N = 6$; t-test

$P = 0.0096$) while the N parameter was not significantly affected (Fig. 4E and F; males t-test $P = 0.49$; females t-test $P = 0.50$). Electrophysiological visual acuity was assessed by stimulating the animal with gratings of different spatial frequency (22). We found that both heterozygous and null animals had a significantly lower spatial resolution (visual acuity) as compared to their sex-matched wt littermates (Fig. 5; wt $N = 5$, *cdkl5* null $N = 6$; t-test $P = 0.011$; wt $N = 7$, *cdkl5* het $N = 6$; t-test $P = 0.0097$).

Early IOS responses are correlated with adult VEP amplitude, visual acuity and contrast response curve

The altered VEP responses found in adult *cdkl5* null and heterozygous mice could result from an abnormal development of neural circuits. Since adult VEP recordings were performed in the same mice employed for IOS assessment, we investigated if there was a correlation between IOS responses during development and adult electrophysiological measurements. For this reason, we computed the correlation matrix between z-scored amplitudes of the contralaterally evoked IOS and VEPs, VEP visual acuity and the C_{50} parameter obtained from contrast curve fit (Fig. 6A). Intriguingly, all these variables were significantly correlated indicating that IOS measures are in agreement with VEPs, and that altered developmental trajectories could be at the basis of the visual impairment found in adult *cdkl5* mutants. These data also suggest that monitoring IOS responses during development could be a predictive tool of adult cortical visual processing.

Visual responses are a robust disease biomarker

To evaluate the reliability of the visual phenotype as a biomarker, we evaluated its accuracy, sensitivity, specificity and d' (Table 1 and Fig 6C) using linear support vector machine (SVM), a supervised machine-learning algorithm for data classification. When trained with the entire dataset (All), the algorithm showed a remarkable discriminative capability ($d' = 1.32$) between mutated and wild-type mice. We then performed a principal components analysis (PCA) and we selected the first two components accounting for 66.7% of the variance in the entire dataset. By using these variables, subjects were readily segregated between wt and mutants (Fig. 6B) and the d' was significantly improved ($d' = 1.52$; one-way ANOVA $P < 0.0001$, post hoc Holm–Sidak All versus PCA $P < 0.0001$). Since ease of testing is a key factor in the applicability of a disease biomarker, we also assessed whether smaller subsets of variables could reach a similar discriminative performance. The tested data subsets were composed of: visual acuity and C_{50} (Thresholds); contralateral and ipsilateral VEP amplitude (VEP); contralateral IOS amplitude at P27–28 and P31–32 (IOS-C); ipsilateral IOS amplitude at P27–28 and P31–32 (IOS-I). As a control we also repeated the procedure after bootstrapping the dataset of principal components (Bootstrap). Thresholds, VEP and IOS-C models showed significantly better performances than the bootstrap condition (Thresholds d' : 1.21, VEP d' : 0.97, IOSI-C d' : 1.00; post hoc Holm–Sidak $P < 0.0001$ for all comparisons versus Bootstrap), indicating that even simple sets of physiological parameters could be used as a tool for monitoring both disease progression and the effect of potential treatments. Interestingly, IOS-I model had a remarkably lower efficiency not significantly different from the Bootstrap model (d' : 0.16; post hoc Holm–Sidak $P = 0.20$).




Figure 2. (A) Images collected at different ages in one male wild-type (WTm) and one *cdkl5* null (KO) mice. Responses to contralateral (Contra) and ipsilateral eye (Ipsi) eye stimulation are reported. (B) IOS amplitude in response to contralateral eye stimulation at different ages in WTm and KO mice. (C) IOS amplitude in response to ipsilateral eye stimulation at different ages in WTm and KO mice. (D) Ocular dominance index (ODI) in WTm and KO mice. (E) Images collected at different ages in one female wt (WTf) and one *cdkl5* heterozygous (HET) mice. Responses to contralateral (Contra) and ipsilateral eye (Ipsi) eye stimulation are reported. (F) IOS amplitude in response to contralateral eye stimulation at different ages in WTf and HET mice. (G) IOS amplitude in response to ipsilateral eye stimulation at different ages in WTf and HET mice. (H) Ocular dominance index (ODI) in WTf and HET mice. In all panels, values are average \pm SEM. * $P < 0.05$, ** $P < 0.01$. Frame size: 2×2 mm.

Discussion

The availability of animal models has greatly benefited the efforts to individuate molecular and cellular underpinnings of *cdkl5* syndrome (9,10). Moreover, behavioral assessment has outlined significant impairments in different domains (9,10,25,26). However, there remains a pressing need for biomarkers of high translational value to non-invasively and quantitatively monitor brain function throughout progression of the disorder and during treatment. Here, we used transcranial IOS and intracortical VEPs to investigate visual cortical function in *cdkl5* mutant mice. The results showed that cortical responses are dramatically reduced in amplitude already at P27-P28, as assessed both with IOS and VEPs, and that this reduction is significantly correlated with decreased response amplitude, abnormal contrast response function, and impaired visual acuity in adult mutants. Importantly, these alterations were detected both in male mice with no expression of *cdkl5* and in heterozygous female mutants with mosaic expression of the remaining *cdkl5* allele. Sensitivity analysis revealed that visual responses were able to correctly classify mice in mutant or wild-type with more than 93% accuracy and 92% sensitivity proving the robustness of this technique in phenotype assessment.

In recent years, the visual cortex has become an important model to assess cortical processing in mouse model of neurodevelopmental disorders (12,27,28). For instance, the use of visually evoked responses has been suggested as a relatively common quantitative method to directly compare cortical function in RTT patients and mouse models carrying *mecp2* mutations (11,12). VEPs have also been used to reveal alterations in West Syndrome patients, EIEE1 (OMIM ref: #308350), and in EIEE3 (OMIM ref: #609304), supporting the translational and clinical applicability of this technique even in presence of seizures or hyperexcitability (29,30). Our results suggest that monitoring deficits in cortical visual function could also be applied to *cdkl5* syndrome. This

possibility is in agreement with clinical studies indicating that *cdkl5* patients show visual impairments (13,15,16). Moreover, previous studies showed that adult *cdkl5* mutant mice have altered neural responses in sensory cortices (9,10) and impaired visual optokinetic reflex (9). A fundamental issue in analyzing phenotypes in mouse models of neurodevelopmental disorders is to understand whether the defective phenotype is a primary deficit occurring at the disease onset or a late secondary manifestation of the disease. Knowledge about the onset of the symptoms is useful to optimize treatment schedule and to formulate hypotheses on the underlying neurobiological defects generating the deficit. Our results indicate that, both in *cdkl5* null males and in heterozygous females, an impairment in visual responses begins to be present during development, in correlation with the increase of *cdkl5* expression occurring during forebrain postnatal development (2,7,8). Furthermore, the degree of impairment of cortical visual responses present in juvenile mutants was correlated with the deficits observed in the same animals when they became adult, suggesting that the alteration of developmental maturation mechanisms by *cdkl5* mutation is responsible for the impaired visual cortical function during adulthood.

Both the onset of visual response impairment in mice and the appearance of symptoms in humans take place during a period of intense synaptogenesis and synaptic plasticity, in agreement with the proposed role of *cdkl5* in synaptic organization (3-6). Studies performed in *cdkl5* mice reported abnormal turnover and density of dendritic spines, and reduced expression of proteins involved in excitatory synaptic structure in different brain areas, including sensory cortices (4,9,26). In particular, a recent morphological analysis focused on the developing visual cortex showed reduced staining for the activity-dependent protein *c-fos* and for key components of the excitatory postsynaptic protein assembly together with increased numbers and




Figure 3. (A) Average VEP amplitude to 0.03 cyc/deg gratings for contralateral and ipsilateral eye stimulation in male wt (WTm) and *cdkl5* null (KO) mice. Representative VEPs from single animals are reported above the corresponding histogram bar. (B) Ratio between contralateral and ipsilateral eye responses (C/I ratio) in WTm and KO mice. (C) Average VEP amplitude to 0.03 cyc/deg gratings for contralateral and ipsilateral eye stimulation in female wt (WTf) and *cdkl5* heterozygous (HET) mice. Representative VEPs from single animals are reported above the corresponding histogram bar. (D) C/I ratio in WTf and HET mice. Horizontal scale bar in (A and C)=50 ms, vertical scale bar in (A and C)=100 μV . In all panels, values are average \pm SEM. * $P < 0.05$.

connectivity of parvalbumin-positive inhibitory interneurons (31). The possibility that *cdkl5* acts both on excitatory and inhibitory neurons is strengthened by previous work showing distinct but overlapping phenotypes in mice with *cdkl5* deletion selectively from excitatory or inhibitory neurons (9). Therefore, a defective maturation of excitatory and inhibitory circuits could contribute to the impaired visual cortical responses observed here.

Intriguingly, our data suggest that the contralateral and the ipsilateral responses could be differentially sensitive to *cdkl5* mutation. Indeed, ipsilateral responses of mutant heterozygous females, albeit consistently reduced, were not statistically affected. Whether this is due to differential effects of *cdkl5* on the crossed and uncrossed pathways, or to the low statistical power due to the combination of low signal-to-noise ratio of mouse ipsilateral responses and the variability intrinsic to *cdkl5* mosaicism, is still to be clarified.

In summary, we found that the developmental trajectory of visual cortical development is altered in *cdkl5* mutants. Our data were obtained with two different techniques that provided highly correlated data increasing the robustness of the results. Moreover, we showed that visual assessment can be used to automatically classify subjects with high reliability. Importantly,




Figure 4. (A) Contrast function for contralateral eye stimulation in male wt (WTm) and *cdkl5* null (KO) mice. Representative examples from single animals are reported. Data points are fitted with the Naka-Rushton function. (B) Contrast function for contralateral eye stimulation in female wt (WTf) and *cdkl5* heterozygous (HET) mice. Representative examples from single animals are reported. Data points are fitted with the Naka-Rushton function. (C) C₅₀ parameter (contrast eliciting half-maximal response) of the Naka-Rushton fit in WTm and KO mice. (D) C₅₀ parameter in WTf and HET mice. (E) N parameter (slope) of the Naka-Rushton fit in WTm and KO mice. (F) N parameter in WTf and HET mice. In all panels, values are average \pm SEM. * $P < 0.05$, ** $P < 0.01$.

VEP and IOS reduction of contralateral responses in both null and het *cdkl5* mice exhibited a large effect size (>1.3) that was obtained with approximately the same number of animals for both sexes, suggesting that contralateral visual response deficit is not linearly dependent on the percentage of cells carrying the mutation. VEP recordings can be readily applied to humans and other species, increasing the translational value of the visual biomarker. Transcranial IOS imaging, a minimally invasive and longitudinal technique, is also comparable to techniques used in humans: indeed, it detects the same blood-oxygenation level dependent signal measured by other widely used methods to assess responsiveness in newborns and infants like functional magnetic resonance imaging or functional near infrared spectroscopy or tomography. We expect that these techniques will be extremely valuable to monitor longitudinally the effectiveness of treatments and washout effects in preclinical, and possibly clinical, studies of novel treatments for *cdkl5* disorder.

Materials and Methods

Animal handling

Animals were maintained in rooms at 22°C with a standard 12-h light-dark cycle. During the light phase a constant illumination below 40 lux from fluorescent lamps was maintained. Food (standard diet, 4RF25 GLP Certificate, Mucedola) and water were available *ad libitum* and changed weekly. Open-top cages (36.5 \times 20.7 \times 14 cm; 26.7 \times 20.7 \times 14 cm for up to 5 adult mice or




Figure 5. (A) Spatial frequency response curve for contralateral eye stimulation in male wild-type (WTm) and *cdkl5* null (KO) mice. Representative examples from single animals are reported. Data points are linearly fitted. (B) VEP visual acuity in WTm and KO mice. (C) Spatial frequency response curve for contralateral eye stimulation in female wt (WTf) and *cdkl5* heterozygous (HET) mice. Representative examples from single animals are reported. Data points are linearly fitted. (D) VEP visual acuity in WTf and HET mice. In all panels, values are average \pm SEM. * $P < 0.05$, ** $P < 0.01$.

42.5 \times 26.6 \times 15.5 cm for up to 8 adult mice) with wooden dust-free bedding were used. All the experiments were carried out in accordance with the directives the European Community Council (2011/63/EU) and approved by the Italian Ministry of Health. All necessary efforts were made to minimize both stress and the number of animals used. The mice used in this work derive from the *cdkl5* null strain in C57BL/6N background developed in (9) and backcrossed in C57BL/6J for three generations. Male wt mice were bred with female hets to obtain mutant and wt littermates. Weaning was performed at P21–23. Genotyping (P10–12) was performed on tail tissue as described in (9). Colony founders were selected for the absence of the *rd8* retinal degeneration allele spontaneously present in C57BL/6N mice (32). The experimental groups were divided by sex: male *cdkl5* null and female heterozygous mice were compared with male wt and female wt littermates, respectively. Data analysis was performed by experimenters blind to the genotype. For chronic evaluation of IOS/VEP responses and for VEP recordings at p27–32, mutant and littermate control animals from 9 and 5 different litters were used, respectively.

Experimental protocol

Mice of the four experimental groups (female wt, female *cdkl5* heterozygous, male wt, male *cdkl5* nulls) underwent three




Figure 6. (A) Correlation matrix between average contralaterally evoked IOS amplitude during development (IOS-C), contralaterally evoked VEP amplitude at P60–80 (VEP-C), VEP acuity at P60–80 (ACUITY), and the C_{50} parameter at P60–80 derived from Naka-Rushton fit of the contrast response curve (C_{50}). Non-parametric Spearman correlation analysis revealed significant correlation (* $P < 0.05$, ** $P < 0.01$, P -values corrected for multiple comparisons using Benjamini-Hochberg false discovery rate) between all the variables. The correlation coefficient R is reported for each correlation in the corresponding plot. (B) Scatter plot of all the experimental subjects analyzed with VEP and IOS imaging plotted in the space of the first two principal components of PCA. (C) Comparison of d' for different SVM classifiers trained and tested, respectively, with: the entire dataset (All), the first two principal components (PCA), Visual acuity and C_{50} parameter from the contrast sensitivity curve (Thresholds), VEP amplitudes (VEP); contralateral IOS amplitudes (IOS-C); ipsilateral IOS amplitudes (IOS-I) and randomly permuted dataset (Bootstrap). n.s., not significant; all other comparisons have $P < 0.05$. Values in C are presented as mean \pm 95% CI.

sessions of IOS imaging during development and VEP recordings at P60–80 (protocol scheme depicted in Fig. 1A). Throughout imaging sessions weight gain was monitored in all animals as a measure of general health status. No differential effect was detected between wild-type and mutant mice (Supplementary Material, Fig. S3). A separate cohort of mice was analyzed at P27–32 using VEPs.

Chronic IOS imaging

Surgery

For chronic IOS preparations, mice (P23–24) were deeply box-anesthetized and maintained with isoflurane (respectively, 3 and 1%), placed on a stereotaxic frame and head fixed using ear bars. Body temperature was controlled using a heating pad and a rectal probe to maintain the animals' body at 37°C. Local anesthesia was provided using subcutaneous lidocaine (2%)

Table 1. Performance evaluation of SVM classifiers trained with different datasets

Training dataset	Accuracy % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)	d' (95% CI)
All	89.96 (89.34–90.58)	89.50 (88.53–90.47)	91.50 (90.14–92.86)	1.32 (1.29 to 1.36)
PCA	93.10 (92.56–93.64)	92.21 (91.11–93.32)	97.08 (96.14–98.03)	1.52 (1.49 to 1.55)
Thresholds	87.63 (86.72–88.55)	83.79 (82.07–85.50)	92.83 (91.24–94.42)	1.21 (1.16 to 1.25)
VEP	82.58 (81.55–83.60)	82.79 (80.78–84.80)	82.50 (80.32–84.68)	0.97 (0.92 to 1.02)
IOS-C	82.94 (81.80–84.08)	85.14 (83.16–87.13)	80.58 (78.65–82.52)	1.00 (0.96 to 1.05)
IOS-I	64.88 (63.58–66.19)	73.43 (71.25–75.61)	53.17 (49.91–56.42)	0.16 (0.06 to 0.25)
Bootstrap	55.94 (54.83–57.06)	49.86 (46.32–53.40)	50.83 (47.22–54.45)	0.08 (–0.03 to 0.19)

IOS, intrinsic optical signal; VEP, visually evoked potentials; SVM, support vector machine; PCA, principal component analysis.

injection and eyes were protected with dexamethasone-based ointment (Tobradex, Alcon Novartis). The scalp was removed and the skull carefully cleaned with saline. Skin was secured to the skull using cyanoacrylate. Then a thin layer of cyanoacrylate is poured over the exposed skull to attach a custom made metal ring (9 mm internal diameter) centered over the binocular visual cortex. When the glue dried off, a drop of transparent nail polish was spread over the area to ameliorate optical access. After surgery the animals were placed in a heated box and monitored to ensure the absence of any sign of discomfort. Before any other experimental procedure, mice were left to recover for 24/48 h. During this period, paracetamol (5 mg/ml) was administered in the water as analgesic therapy.

Visual stimulation, data acquisition and analysis

IOS recordings were performed under avertin anesthesia (20 μ l/g, i.p.) at P25–26, P27–28 and P31–32. Images were visualized using an Olympus microscope (BX50WI). Red light illumination was provided by 8 red LEDs (625 nm, Knight Lites KSB1385-1P) attached to the objective (Zeiss Plan-NEOFLUAR 5x, NA: 0.16) using a custom made metal LED holder (33). The animal was secured under the objective using a ring-shaped neodymium magnet (www.supermagnete.it; date last accessed April 1, 2017, R-12-09-1.5-N) mounted on an arduino-based 3D printed imaging chamber that also controls eye shutters and a thermostated heating pad (Fig. 1B; <http://labrigger.com/blog/2015/11/30/open-source-intrinsic-imaging/>; date last accessed April 1, 2017). Visual stimuli were generated using Matlab Psychtoolbox and presented on a gamma corrected 9.7 in. monitor, placed 10 cm away from the eyes of the mouse. Square wave gratings were presented in the binocular portion of the visual field (-10° to $+10^\circ$ relative to the horizontal midline and -5° to $+50^\circ$ relative to the vertical midline) with a spatial frequency of 0.03 cyc/deg, mean luminance 20 cd/m² and a contrast of 90%. The stimulus consisted in the abrupt contrast reversal of a grating with a temporal frequency of 4 Hz for 1 s, time locked with a 16-bit depth acquisition camera (Hamamatsu digital camera C11440) using a parallel port trigger. Interstimulus time was 14 s. Frames were acquired at 30 fps with a resolution of 512 \times 512 pixels. A total of 210 frames were captured for each trial: 30 before the stimulus as a baseline condition and 180 as post-stimulus. The signal was averaged for at least 30 trials and downsampled to 10 fps. Fluctuations of reflectance (R) for each pixel were computed as the normalized difference from the average baseline ($\Delta R/R$). For each recording, an image representing the mean evoked response was computed by averaging frames between 0.5 and 2.5 seconds after stimulation. The mean image was then low-pass filtered with a 2D average spatial filter (30 pixels, 117 μ m² square kernel). To select the binocular portion of the primary visual cortex for further analysis, a region of interest (ROI) was

automatically calculated on the mean image of the response to ipsilateral stimulation by selecting the pixels in the lowest 30% $\Delta R/R$ of the range between the maximal and minimal intensity pixel (34). The same ROI was used for the analysis of contralateral eye responses. A scheme of the data processing is shown in Figure 1D. Mean evoked responses were quantitatively estimated as the average intensity inside the ROI. ODI was calculated as $(C - I)/(C + I)$ for each pixel, where C and I indicate the amplitude of contralateral and ipsilateral responses, respectively (34). To weaken background fluctuations a manually selected polygonal region of reference (ROR) was subtracted. The ROR was placed where no stimulus response, blood vessel artifact or irregularities of the skull were observed (35). An example of the time course of the $\Delta R/R$ response to visual stimulation after processing is shown in Figure 1C.

Visually evoked potentials

Surgery

General anesthesia was induced in mice with 3% isoflurane, subsequently deeply anesthetized with an intraperitoneal injection of urethane (0.7 ml/h g; 20% solution in lactated ringer solution) and head-fixed in a stereotaxic frame. After the removal of the ring implant, the skull was exposed and a small craniotomy (2 \times 2 mm) overlying the visual cortex was performed, leaving the dura mater intact. Then, a multichannel neural probe (Q-trode tetrode configuration, Neuronexus) was slowly inserted at a depth of 150–200 μ m, in the binocular visual cortex (lambda: +3.2 mm lateral, +0.2 mm rostral and following IOS derived coordinates), where a high amplitude positive VEP is detectable. Signal was acquired using Cheetah 32 (Neuralynx) recording system at 30.3 kHz of sampling rate with a band pass filter of 0.1–250 Hz. Signal from each channel was averaged to obtain VEPs.

Visual stimulation and data acquisition

Both stimuli and analysis for VEP recordings were performed using custom software written in Matlab Psychtoolbox and displayed onto a gamma corrected 21 inch CRT monitor placed 20 cm in front of the animal. Stimuli consisted in contrast reversal square wave gratings with a spatial frequency of 0.03 cyc/deg, mean luminance of 25 cd/m² and a contrast of 90%. Monitor was centered on animal head and stimuli covered $\pm 55^\circ$ relative to vertical and -5° to $+30^\circ$ relative to vertical midline. Stimulus temporal frequency was 2 Hz. VEP responses were averaged for at least 100 trials per eye. Each condition was repeated for at least eight times. The amplitude quantification of the response was calculated as the peak to baseline difference of the first positive component (at ~ 100 ms). Visual acuity is calculated presenting contrast reversal sinewave gratings with

different spatial frequencies (0.03, 0.06, 0.012, 0.024, 0.048, 0.96 and 0 cyc/deg) and calculating the maximal spatial frequency resolved by linear fit estimation of parameters and extrapolation of amplitude at 0 μ V in a semi-logarithmic space. Contrast sensitivity was calculated using 0.03 cyc/deg contrast reversal sine wave gratings with different contrasts (90, 50, 25, 12, 6, 3 and 0%). Normalized amplitude data was fitted to a sigmoid curve using Naka-Rushton function, $\text{Resp}(c) = 1 C^n / (C_{50}^n + C^n)$, to extract contrast sensitivity parameters (23,24,36). C_{50} is the contrast evoking half the maximum response and n describes the shape of the curve.

SVM classifier

Z-scored values of each physiological parameter were used for linear SVM classification. SVM is a supervised machine learning method for data classification that can be trained to find the best hyperplane that separates all data points in two user-defined classes and can subsequently be exploited to blind-predict the class to which a new observation belongs (37–39). We defined two classes: mutated (heterozygous and null) and wild-type (males and females) mice. By using the Matlab function *svmtrain*, we trained the SVM with a subset of data consisting of 50% of the dataset and we then used the remaining 50% for testing, using the *svmclassify* function. Accuracy, sensitivity, specificity and D-prime (d') were then computed for the categorical classification in order to evaluate its performance. This procedure was repeated 200 times, each one with a randomly divided training and testing subsets. Values for accuracy, sensitivity (or true positive rate), specificity (or true negative rate) and d' were averaged across iterations. Accuracy, sensitivity and specificity were defined as $(TP + TN)/\text{total}$, TP/P and TN/N , respectively, where TP: True positive, TN: True Negative, P: total positives, N: total negatives. D-prime, which measures the distance between the signal and the noise means in standard deviation units (40), was calculated using matlab function *dprime_simple* (<https://it.mathworks.com/matlabcentral/fileexchange/47711-dprime-simple-m>; date last accessed April 1, 2017).

Statistical analysis

All statistical analyses were performed using GraphPad Prism version 6 (GraphPad Software, San Diego, CA, USA). All values were presented as mean \pm SEM unless otherwise stated. Differences between groups were tested for significance using two-way ANOVA, unless otherwise indicated. Holm-Sidak's multiple comparisons *post hoc* tests were performed, where appropriate, to correct for multiple hypothesis testing. In the figures, n.s., not significant, * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$.

Supplementary Material

Supplementary Material is available at HMG online.

Acknowledgements

We thank Areg Barsegyan for technical suggestions on imaging implants.

Conflict of Interest statement. None declared.

Funding

International Foundation for cdkl5 Research and the Fondazione Telethon (GGP15098). Funding to pay the Open Access publication charges for this article was provided by Fondazione Telethon.

References

- Fehr, S., Wilson, M., Downs, J., Williams, S., Murgia, A., Sartori, S., Vecchi, M., Ho, G., Polli, R., Psoni, S. et al. (2012) The cdkl5 disorder is an independent clinical entity associated with early-onset encephalopathy. *Eur. J. Hum. Genet.*, **21**, 266–273.
- Rusconi, L., Salvatoni, L., Giudici, L., Bertani, I., Kilstrup-Nielsen, C., Broccoli, V. and Landsberger, N. (2008) cdkl5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail. *J. Biol. Chem.*, **283**, 30101–30111.
- Ricciardi, S., Ungaro, F., Hambrook, M., Rademacher, N., Stefanelli, G., Brambilla, D., Sessa, A., Magagnotti, C., Bachi, A., Giarda, E. et al. (2012) cdkl5 ensures excitatory synapse stability by reinforcing NGL-1–PSD95 interaction in the post-synaptic compartment and is impaired in patient iPSC-derived neurons. *Nat. Cell Biol.*, **14**, 911–923.
- Della Sala, G., Putignano, E., Chelini, G., Melani, R., Calcagno, E., Michele Ratto, G., Amendola, E., Gross, C.T., Giustetto, M. and Pizzorusso, T. (2016) Dendritic spine instability in a mouse model of cdkl5 disorder is rescued by insulin-like growth factor 1. *Biol. Psychiatry*, **80**, 302–311.
- Zhang, Y., Matt, L., Patriarchi, T., Malik, Z.A., Chowdhury, D., Park, D.K., Renieri, A., Ames, J.B. and Hell, J.W. (2014) Capping of the N-terminus of PSD5 by calmodulin triggers its postsynaptic release. *EMBO J*, **33**, 1341–53. doi:10.1002/embj.201488126.
- Zhu, Y.-C., Li, D., Wang, L., Lu, B., Zheng, J., Zhao, S.-L., Zeng, R. and Xiong, Z.-Q. (2013) Palmitoylation-dependent cdkl5-PSD-95 interaction regulates synaptic targeting of cdkl5 and dendritic spine development. *Proc. Natl. Acad. Sci.*, **110**, 9118–9123.
- Chen, Q., Zhu, Y.-C., Yu, J., Miao, S., Zheng, J., Xu, L., Zhou, Y., Li, D., Zhang, C., Tao, J. et al. (2010) cdkl5, a protein associated with Rett syndrome, regulates neuronal morphogenesis via Rac1 signaling. *J. Neurosci.*, **30**, 12777–12786.
- Hector, R.D., Dando, O., Landsberger, N., Kilstrup-Nielsen, C., Kind, P.C., Bailey, M.E.S. and Cobb, S.R. (2016) Characterisation of cdkl5 transcript isoforms in human and mouse. *PLoS One*, **11**, e0157758.
- Amendola, E., Zhan, Y., Mattucci, C., Castroflorio, E., Calcagno, E., Fuchs, C., Lonetti, G., Silingardi, D., Vyssotski, A.L., Farley, D. et al. (2014) Mapping pathological phenotypes in a mouse model of cdkl5 disorder. *PLoS One*, **9**, e91613.
- Wang, I.-T.J., Allen, M., Goffin, D., Zhu, X., Fairless, A.H., Brodtkin, E.S., Siegel, S.J., Marsh, E.D., Blendy, J.A. and Zhou, Z. (2012) Loss of cdkl5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice. *Proc. Natl. Acad. Sci.*, **109**, 21516–21521.
- LeBlanc, J.J., DeGregorio, G., Centofante, E., Vogel-Farley, V.K., Barnes, K., Kaufmann, W.E., Fagiolini, M. and Nelson, C.A. (2015) Visual evoked potentials detect cortical processing deficits in Rett syndrome. *Ann. Neurol.*, **78**, 775–786.
- Durand, S., Patrizi, A., Quast, K.B., Hachigian, L., Pavlyuk, R., Saxena, A., Carninci, P., Hensch, T.K. and Fagiolini, M. (2012)

- NMDA receptor regulation prevents regression of visual cortical function in the absence of *Mecp2*. *Neuron*, **76**, 1078–1090.
13. Moseley, B.D., Dhamija, R., Wirrell, E.C. and Nickels, K.C. (2012) Historic, clinical, and prognostic features of epileptic encephalopathies caused by *cdkl5* mutations. *Pediatr. Neurol.*, **46**, 101–105.
 14. Bahi-Buisson, N., Nectoux, J., Rosas-Vargas, H., Milh, M., Boddaert, N., Girard, B., Cances, C., Ville, D., Afenjar, A., Rio, M. et al. (2008) Key clinical features to identify girls with *cdkl5* mutations. *Brain*, **131**, 2647–2661.
 15. Paine, S.M.L., Munot, P., Carmichael, J., Das, K., Weber, M.A., Prabhakar, P. and Jacques, T.S. (2012) The neuropathological consequences of *cdkl5* mutation. *Neuropathol. Appl. Neurobiol.*, **38**, 744–747.
 16. Stalpers, X.L., Spruijt, L., Yntema, H.G. and Verrips, A. (2012) Clinical phenotype of 5 females with a *cdkl5* mutation. *J. Child Neurol.*, **27**, 90–93.
 17. Melani, F., Mei, D., Pisano, T., Savasta, S., Franzoni, E., Ferrari, A.R., Marini, C. and Guerrini, R. (2011) *cdkl5* gene-related epileptic encephalopathy: electroclinical findings in the first year of life. *Dev. Med. Child Neurol.*, **53**, 354–360.
 18. Espinosa, J.S., Sebastian Espinosa, J. and Stryker, M.P. (2012) Development and plasticity of the primary visual cortex. *Neuron*, **75**, 230–249.
 19. Riddell, P.M., Ladenheim, B., Mast, J., Catalano, T., Nobile, R. and Hainline, L. (1997) Comparison of measures of visual acuity in infants: Teller acuity cards and sweep visual evoked potentials. *Optom. Vis. Sci.*, **74**, 702–707.
 20. Kang, E., Durand, S., LeBlanc, J.J., Hensch, T.K., Chen, C. and Fagiolini, M. (2013) Visual acuity development and plasticity in the absence of sensory experience. *J. Neurosci.*, **33**, 17789–17796.
 21. Prusky, G.T. and Douglas, R.M. (2003) Developmental plasticity of mouse visual acuity. *Eur. J. Neurosci.*, **17**, 167–173.
 22. Porciatti, V., Pizzorusso, T. and Maffei, L. (1999) The visual physiology of the wild type mouse determined with pattern VEPs. *Vis. Res.*, **39**, 3071–3081.
 23. Albrecht, D.G. and Hamilton, D.B. (1982) Striate cortex of monkey and cat: contrast response function. *J. Neurophysiol.*, **48**, 217–237.
 24. Naka, K.I. and Rushton, W.A. (1966) S-potentials from colour units in the retina of fish (Cyprinidae). *J. Physiol.*, **185**, 536–555.
 25. Fuchs, C., Rimondini, R., Viggiano, R., Trazzi, S., De Franceschi, M., Bartesaghi, R. and Ciani, E. (2015) Inhibition of GSK3 β rescues hippocampal development and learning in a mouse model of *cdkl5* disorder. *Neurobiol. Dis.*, **82**, 298–310.
 26. Trazzi, S., Fuchs, C., Viggiano, R., De Franceschi, M., Valli, E., Jedynak, P., Hansen, F.K., Perini, G., Rimondini, R., Kurz, T. et al. (2016) HDAC4: a key factor underlying brain developmental alterations in *cdkl5* disorder. *Hum. Mol. Genet.*, **25**, 3887–3907.
 27. Begenisic, T., Sansevero, G., Baroncelli, L., Cioni, G. and Sale, A. (2015) Early environmental therapy rescues brain development in a mouse model of Down syndrome. *Neurobiol. Dis.*, **82**, 409–419.
 28. Boggio, E.M., Pancrazi, L., Gennaro, M., Lo Rizzo, C., Mari, F., Meloni, I., Ariani, F., Panighini, A., Novelli, E., Biagioni, M. et al. (2016) Visual impairment in FOXP1-mutated individuals and mice. *Neuroscience*, **324**, 496–508.
 29. de Freitas Dotto, P., Cavascan, N.N., Berezovsky, A., Sacai, P.Y., Rocha, D.M., Pereira, J.M. and Salomão, S.R. (2014) Sweep visually evoked potentials and visual findings in children with West syndrome. *Eur. J. Paediatr. Neurol.*, **18**, 201–210.
 30. Molinari, F., Raas-Rothschild, A., Rio, M., Fiermonte, G., Encha-Razavi, F., Palmieri, L., Palmieri, F., Ben-Neriah, Z., Kadhom, N., Vekemans, M. et al. (2005) Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. *Am. J. Hum. Genet.*, **76**, 334–339.
 31. Pizzo, R., Gurgone, A., Castroflorio, E., Amendola, E., Gross, C., Sassoè-Pognetto, M. and Giustetto, M. (2016) Lack of *Cdkl5* disrupts the organization of excitatory and inhibitory synapses and parvalbumin interneurons in the primary visual cortex. *Front. Cell. Neurosci.*, **10**, 261.
 32. Mattapallil, M.J., Wawrousek, E.F., Chan, C.-C., Zhao, H., Roychoudhury, J., Ferguson, T.A. and Caspi, R.R. (2012) The *Rd8* mutation of the *Crb1* gene is present in vendor lines of C57BL/6N mice and embryonic stem cells, and confounds ocular induced mutant phenotypes. *Invest. Ophthalmol. Vis. Sci.*, **53**, 2921–2927.
 33. Harrison, T.C., Sigler, A. and Murphy, T.H. (2009) Simple and cost-effective hardware and software for functional brain mapping using intrinsic optical signal imaging. *J. Neurosci. Methods*, **182**, 211–218.
 34. Cang, J., Kalatsky, V.A., Löwel, S. and Stryker, M.P. (2005) Optical imaging of the intrinsic signal as a measure of cortical plasticity in the mouse. *Vis. Neurosci.*, **22**, 685–691.
 35. Heimel, J.A., Alexander Heimel, J., Hartman, R.J., Hermans, J.M. and Levelt, C.N. (2007) Screening mouse vision with intrinsic signal optical imaging. *Eur. J. Neurosci.*, **25**, 795–804.
 36. Sarnaik, R., Chen, H., Liu, X. and Cang, J. (2014) Genetic disruption of the On visual pathway affects cortical orientation selectivity and contrast sensitivity in mice. *J. Neurophysiol.*, **111**, 2276–2286.
 37. Pereira, F., Mitchell, T. and Botvinick, M. (2009) Machine learning classifiers and fMRI: a tutorial overview. *Neuroimage*, **45**, S199–S209.
 38. Orrù, G., Pettersson-Yeo, W., Marquand, A.F., Sartori, G. and Mechelli, A. (2012) Using support vector machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review. *Neurosci. Biobehav. Rev.*, **36**, 1140–1152.
 39. Cortes, C. and Vapnik, V. (1995) Support-vector networks. *Mach. Learn.*, **20**, 273–297.
 40. Stanislaw, H. and Todorov, N. (1999) Calculation of signal detection theory measures. *Behav. Res. Methods Instrum. Comput.*, **31**, 137–149.